FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163560807> ?p ?o ?g. }

• W2163560807 endingPage "1824" @default.
• W2163560807 startingPage "1818" @default.
• W2163560807 abstract "Adenotonsillar hypertrophy (ATH) is a frequent cause of upper airways obstructive syndromes associated to middle ear and paranasal sinuses disorders, swallowing and voice disorders, sleep quality disorders, and occasionally facial dysmorphisms. ATH treatment is essentially based on a number of medical–surgical aids including nasal irrigation with topical antibiotics and corticosteroids and/or treatment with systemic corticosteroids, immunoregulators, thermal treatments, adenotonsillectomy, etc. The aim of the present study is to assess the efficacy of Aerosal® halotherapy in the treatment of sub-obstructive adenotonsillar disease and correlated conditions compared to placebo treatment. A total of 45 patients with sub-obstructive adenotonsillar hypertrophy were randomized to receive either Aerosal® halotherapy or placebo for 10 treatment sessions. The main outcome was a reduction greater than or equal to 25% from the baseline of the degree of adenoid and/or tonsillar hypertrophy. In the intention-to-treat analysis, a reduction of the degree of adenoid and/or tonsillar hypertrophy ≥25% from baseline after 10 therapy sessions was found in 44.4% of the patients in the halotherapy arm and in 22.2% of the patients in the placebo arm (P = 0.204). Among the secondary outcomes, the reduction of hearing loss after 10 treatment sessions in the halotherapy arm was higher than the placebo arm (P = 0.018) as well as the time-dependent analysis showed significantly improved peak pressure in the Aerosal® group (P = 0.038). No side effects were reported during the trial. In addition, the therapy was well accepted by the young patients who considered it as a time for play rather than a therapy. Aerosal® halotherapy can be considered a viable adjunct, albeit not a replacement, to conventional medical treatment of sub-obstructive adenotonsillar syndrome and related conditions. Further research is however needed to improve ATH treatment." @default.
• W2163560807 created "2016-06-24" @default.
• W2163560807 creator A5004220538 @default.
• W2163560807 creator A5015642670 @default.
• W2163560807 creator A5037457499 @default.
• W2163560807 creator A5048499966 @default.
• W2163560807 creator A5071426294 @default.
• W2163560807 creator A5079670620 @default.
• W2163560807 creator A5080662298 @default.
• W2163560807 date "2013-11-01" @default.
• W2163560807 modified "2023-09-27" @default.
• W2163560807 title "Double-blind placebo-controlled randomized clinical trial on the efficacy of Aerosal® in the treatment of sub-obstructive adenotonsillar hypertrophy and related diseases" @default.
• W2163560807 cites W1708208039 @default.
• W2163560807 cites W1766220812 @default.
• W2163560807 cites W1775807954 @default.
• W2163560807 cites W1976734975 @default.
• W2163560807 cites W1979933646 @default.
• W2163560807 cites W1984369245 @default.
• W2163560807 cites W1986834309 @default.
• W2163560807 cites W1995727294 @default.
• W2163560807 cites W2002548008 @default.
• W2163560807 cites W2005757130 @default.
• W2163560807 cites W2009857344 @default.
• W2163560807 cites W2016526090 @default.
• W2163560807 cites W2027650661 @default.
• W2163560807 cites W2027700840 @default.
• W2163560807 cites W2049984864 @default.
• W2163560807 cites W2057456741 @default.
• W2163560807 cites W2066849604 @default.
• W2163560807 cites W2072226262 @default.
• W2163560807 cites W2077566557 @default.
• W2163560807 cites W2081513607 @default.
• W2163560807 cites W2092695267 @default.
• W2163560807 cites W2100905560 @default.
• W2163560807 cites W2103043501 @default.
• W2163560807 cites W2119970533 @default.
• W2163560807 cites W2131792955 @default.
• W2163560807 cites W2138143254 @default.
• W2163560807 cites W2152978497 @default.
• W2163560807 cites W2403616740 @default.
• W2163560807 cites W2414534368 @default.
• W2163560807 cites W2415357849 @default.
• W2163560807 cites W2611320035 @default.
• W2163560807 cites W4210608028 @default.
• W2163560807 cites W4230550653 @default.
• W2163560807 cites W4232202719 @default.
• W2163560807 cites W4365805891 @default.
• W2163560807 doi "https://doi.org/10.1016/j.ijporl.2013.08.013" @default.
• W2163560807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24041858" @default.
• W2163560807 hasPublicationYear "2013" @default.
• W2163560807 type Work @default.
• W2163560807 sameAs 2163560807 @default.
• W2163560807 citedByCount "5" @default.
• W2163560807 countsByYear W21635608072015 @default.
• W2163560807 countsByYear W21635608072020 @default.
• W2163560807 countsByYear W21635608072021 @default.
• W2163560807 countsByYear W21635608072022 @default.
• W2163560807 countsByYear W21635608072023 @default.
• W2163560807 crossrefType "journal-article" @default.
• W2163560807 hasAuthorship W2163560807A5004220538 @default.
• W2163560807 hasAuthorship W2163560807A5015642670 @default.
• W2163560807 hasAuthorship W2163560807A5037457499 @default.
• W2163560807 hasAuthorship W2163560807A5048499966 @default.
• W2163560807 hasAuthorship W2163560807A5071426294 @default.
• W2163560807 hasAuthorship W2163560807A5079670620 @default.
• W2163560807 hasAuthorship W2163560807A5080662298 @default.
• W2163560807 hasBestOaLocation W21635608071 @default.
• W2163560807 hasConcept C112497637 @default.
• W2163560807 hasConcept C126322002 @default.
• W2163560807 hasConcept C141071460 @default.
• W2163560807 hasConcept C142724271 @default.
• W2163560807 hasConcept C167414201 @default.
• W2163560807 hasConcept C168563851 @default.
• W2163560807 hasConcept C197934379 @default.
• W2163560807 hasConcept C204787440 @default.
• W2163560807 hasConcept C27081682 @default.
• W2163560807 hasConcept C2776008533 @default.
• W2163560807 hasConcept C2777346780 @default.
• W2163560807 hasConcept C2779073326 @default.
• W2163560807 hasConcept C2781163425 @default.
• W2163560807 hasConcept C71924100 @default.
• W2163560807 hasConceptScore W2163560807C112497637 @default.
• W2163560807 hasConceptScore W2163560807C126322002 @default.
• W2163560807 hasConceptScore W2163560807C141071460 @default.
• W2163560807 hasConceptScore W2163560807C142724271 @default.
• W2163560807 hasConceptScore W2163560807C167414201 @default.
• W2163560807 hasConceptScore W2163560807C168563851 @default.
• W2163560807 hasConceptScore W2163560807C197934379 @default.
• W2163560807 hasConceptScore W2163560807C204787440 @default.
• W2163560807 hasConceptScore W2163560807C27081682 @default.
• W2163560807 hasConceptScore W2163560807C2776008533 @default.
• W2163560807 hasConceptScore W2163560807C2777346780 @default.
• W2163560807 hasConceptScore W2163560807C2779073326 @default.
• W2163560807 hasConceptScore W2163560807C2781163425 @default.
• W2163560807 hasConceptScore W2163560807C71924100 @default.
• W2163560807 hasIssue "11" @default.
• W2163560807 hasLocation W21635608071 @default.
• W2163560807 hasLocation W21635608072 @default.

• next